Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
B.1.1.193NWon-NCAATGCTGCAATCGTGCTAC20502873228751F-18487.6South Korea
B.1.146NWon-NCAATGCTGCAATCGTGCTAC20502873228751F-18487.6South Korea
BQ.1.1.8NCorman-NCACATTGGCACCCGCAATC1957.892870628724F-18489.7Germany
B.1.177.62SNIID WH-1 Seq F24383R24865AAGACTCACTTTCTTCCACAG2142.862436624386F-18509.5Japan
B.1.639SNIID WH-1 Seq F24383R24865AAGACTCACTTTCTTCCACAG2142.862436624386F-18509.5Japan
B.1.372SNIID WH-1 Seq F24383R24865AAGACTCACTTTCTTCCACAG2142.862436624386F-18509.5Japan
BA.2.13SNIID WH-1 Seq F24383R24865AAGACTCACTTTCTTCCACAG2142.862436624386F-18509.5Japan
B.1.489SNIID WH-1 Seq F24383R24865AAGACTCACTTTCTTCCACAG2142.862436624386F-18509.5Japan
B.1.607SNIID WH-1 Seq F24383R24865AAGACTCACTTTCTTCCACAG2142.862436624386F-18509.5Japan
B.1.44SNIID WH-1 Seq F24383R24865AAGACTCACTTTCTTCCACAG2142.862436624386F-18509.5Japan
P.1 (Gamma)SNIID WH-1 Seq F24383R24865AAGACTCACTTTCTTCCACAG2142.862436624386F-18509.5Japan
JK.1ECharité-EACAGGTACGTTAATAGTTAATAGCGT2634.622626926294F-18511.4Germany
B.1.1.329NChan-NTTGGATCTTTGTCATCCAATTTG2334.782930629284R-18512.9China
B.1.1.528NChan-NTTGGATCTTTGTCATCCAATTTG2334.782930629284R-18512.9China
B.53NChan-NTTGGATCTTTGTCATCCAATTTG2334.782930629284R-18512.9China
AY.112.1 (Delta)NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-18513.9US
B.1.1.25NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-18513.9US
CL.1.3NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-18513.9US
FF.1ENiu-ETTCTTGCTTTCGTGGTATTC20402630326322F-18517.5China
B.1.1.360SNIID WH-1 Seq F24383R24865AAGACTCACTTTCTTCCACAG2142.862436624386F-18524.3Japan
EG.10NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-18526.8US
FL.13.3.1NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-18526.8US
FL.17.1NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-18526.8US
XDLNUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-18526.8US
FL.15.2NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-18526.8US
EG.2.2NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-18526.8US
XBB.1.16.32NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-18526.8US
HN.4.1.1NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-18526.8US
FY.4NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-18526.8US
FY.5.3NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-18526.8US
FL.2.2NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-18526.8US
XDHNUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-18526.8US
EG.1.7NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-18526.8US
FY.6.1NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-18526.8US
HU.2NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-18526.8US
EG.1.4.1NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-18526.8US
KJ.1NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-18526.8US
GY.4NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-18526.8US
FY.7NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-18526.8US
FL.17.2NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-18526.8US
EG.12NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-18526.8US
FL.10.2NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-18526.8US
FL.19.1NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-18526.8US
XBB.1.16.19NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-18526.8US
XBB.1.23NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-18526.8US
HK.34.1NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-18526.8US
FY.8.1.1NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-18526.8US
GY.9NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-18526.8US
B.1.640.1NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-18526.8US
FL.4.7NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-18526.8US
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used